Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

NCT05059522 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

68

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Malignancies
NSCLC
Ovarian Cancer
Urothelial Cancer
Solid Tumors

Interventions

DRUG: Avelumab
DRUG: Lorlatanib
DRUG: Talazoparib
DRUG: Pemetrexed
DRUG: Axitinib
DRUG: CMP 001
DRUG: Utomilumab
DRUG: PF04518600

Sponsor

Pfizer